Ovarian Cancer Clinical Trial
Official title:
Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and
cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or
die. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine
when given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they
work in treating patients with progressive or relapsed metastatic germ cell tumors.
OBJECTIVES:
- To determine the maximum tolerated dose (MTD) of gemcitabine hydrochloride when
administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin
with growth factor support (Gem-TIP) in patients with progressive or relapsed
metastatic germ cell tumors.
- To compare the MTD of the Gem-TIP regimen with the MTD determined in a previous Medical
Research Council study of TIP alone.
- To compare the degree of dose intensification achieved with Gem-TIP chemotherapy with
that achieved in the prior study of TIP chemotherapy alone.
- To assess the dose of gemcitabine hydrochloride that can be delivered with the TIP
regimen in these patients.
- To measure response rates and failure-free survival of patients treated with Gem-TIP
alone.
- To assess the utility of PET scanning after Gem-TIP chemotherapy in these patients.
OUTLINE: This is a multicenter, phase I dose-escalation study of gemcitabine hydrochloride
followed by a phase II study.
- Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel
IV over 3 hours on day 1, cisplatin IV over 4 hours on days 1-5, and ifosfamide IV over
1 hour on days 2-6. Patients also receive filgrastim or lenograstim (G-CSF)
subcutaneously (SC) on days 7-18 or until blood counts recover OR pegfilgrastim SC once
on day 6. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease
progression or unacceptable toxicity.
- Phase II: An additional cohort of 14 patients is treated as in phase I at the MTD
determined in phase I.
After completion of study therapy, patients are followed periodically for up to 1 year and
then at the investigator's discretion.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |